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 Oral cancer constitutes the sixth most common cancer worldwide and third 
most common cancer in South-East Asia1. Oral squamous cell carcinoma (OSCC), the 
most common type of oral cancer is often preceded by potentially malignant lesions 
or conditions such as leukoplakia and oral submucous fibrosis (OSF). On biopsy, 
most leukoplakias show histologic features of epithelial dysplasia. The 
standardization of histopathological diagnosis and grading of epithelial dysplasia 
remains subjective as there are many composite histologic criteria of cellular atypia 
and architectural disturbances2. OSF is a well recognized potentially malignant 
condition that is characterized by rigidity of oral mucosa and development of palpable 
fibrous bands, resulting from the deposition of collagen in juxtaepithelial and 
submucosal layers. The malignant transformation rate for leukoplakia ranges from 15-
20%3, while transformation rates as high as 7.6% over a 10-year period have been 
reported for OSF4. 
 
  It has been generally considered that oral carcinogenesis develops through a 
multistep process of accumulation of genetic mutations related to cell proliferation 
and differentiation. The principal targets of genetic damage include growth-promoting 
protooncogenes, growth-inhibiting tumor suppressor genes and genes that regulate 
apoptosis. Mutations in the tumor suppressor p53 gene and resultant alteration in the 
protein are the most common abnormalities found in squamous cell carcinoma of the 
head and neck region2,5.The p53 gene encodes a 53 kD nuclear phosphoprotein that is 
involved in DNA repair, programmed cell death and negative regulation of cell cycle. 
In normal cells, wild type p53 protein has a very short half life (6-20 minutes) and is 
present in such small quantities that it cannot be detected by immunohistochemical 
methods. However, mutations in p53 gene often result in a more stable product and 
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prolong the half life of p53 protein, causing it to accumulate within cell nuclei to the 
extent that it can be easily detected by immunohistochemistry5. 
 
 The p63 gene mapped on chromosome 3q27-29 is a member of p53 gene 
family and is responsible for the transcription two groups of p63 protein (TAp63 and 
ΔNp63), both of which have α, β and γ isoforms. The TAp63 group contains an N-
terminal transactivation domain and has functions similar to p53 such as, cell cycle 
arrest, apoptosis and cell differentiation. The ΔNp63 group lacks TA 
(Transactivation) domain and acts by inhibiting both p53 and TA p63 and thus favors 
cell proliferation6. It is suggested that p63, possibly in concert with p53 may play a 
role in the regulation of proliferation and differentiation in potentially malignant 
disorders and malignant lesions of the oral cavity7.  
 
 This study is done to evaluate the expression of p53 and p63 proteins in 
OSCC, oral leukoplakia and OSF by immunohistochemistry. 
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AIMS AND OBJECTIVES: 
 l. To evaluate the expression of p53 and p63 proteins in formalin fixed, paraffin 
embedded  sections of OSCC, oral leukoplakia and OSF specimens by 
immunohistochemistry. 
 
2. To compare the expression of p53 and p63 proteins in formalin fixed, paraffin 







There is altered expression of p53 and p63 proteins in  
- Oral squamous cell carcinoma 
- Oral leukoplakia 
- Oral submucous fibrosis 





The study was conducted in the Department of Oral and Maxillofacial 
Pathology, Ragas Dental College and Hospital, Chennai. 
Study subjects: 
20 consecutive cases of oral squamous cell carcinoma (Group I), 20 
consecutive cases of clinically diagnosed oral leukoplakia (Group II), 20 consecutive 
cases of OSF (Group III), and 10 cases of normal patients (Group IV), were collected 
over a period of 6 months. A preformatted  clinical case sheet was used to record all 
the cases. Detailed case history including age, sex, and occupation, past medical and 
dental history along with the history of habits were recorded. This was followed by 
general examination and intra oral examination. 
Selection criteria: 
Group I: Clinically and histopathologically confirmed cases of OSCC (Figure 3). 
Group II: Clinically appearing white, non-scrapable patch associated with the history 
of tobacco habit, which was clinically diagnosed as leukoplakia and 
histopathologically graded as epithelial dysplasia (mild, moderate or severe)     
(Figure 4).  
Group III: The criteria for selection of OSF patients were difficulty in opening the 
mouth, burning sensation of the mouth, palpable vertical fibrous bands in the oral 
mucosa and history of areca nut chewing (Figure 5). 
Group IV: Ten patients who reported to the outpatient department of Oral and 





Incisional biopsy of sufficient width and depth to ensure inclusion of 
connective tissue was taken from the buccal mucosa of the 60 study patients. Normal 
non-inflammed buccal mucosa adjacent to the site of surgery was biopsied for the 
control group. Informed consent was obtained from all the patients. The tissues taken 
were immediately transferred to 10% buffered formalin for further processing. After 
adequate fixation, paraffin blocks of the tissues were made. 
 
IMMUNOHISTOCHEMISTRY PROCEDURE:  
Armamentarium (Figure1): 
• Microtome  
• Autoclave  
• Hot air oven  
• Couplin jars  
• Measuring jar  
• Refrigerator 
• Weighing machine DHONA 200D  
• Cyclomixer 
• APES (3-amino propyl triethoxy silane) coated slides  
• Slide carrier 
• Slide warmer 
• Aluminum foil  
• Micropipettes  
• Tooth forceps 




• Rectangular steel trays with glass rods  
• Sterile gauze 
• Cover-slips 
• Light microscope 
 
Reagents for IHC: 
1. Conc. HCL 
2. Laxbro solution 
3. APES (3-Amino Propyl Triethoxy Silane)  
4. Acetone 
5. Citrate buffer (pH 6) 
6. Phosphate buffer saline (pH 7.2-7.4)  
7. 3% hydrogen peroxide (H2O2) 
8. Deionized distilled water  
9. Haematoxylin 
10. Eosin 
1 l. Alcohol 70% 










Antibodies used (Figure 2): 
1. Primary antibody 
a. Monoclonal mouse anti-human p53 (DO7, Biogenex)  
b. Monoclonal mouse anti-human p63 (4A4, Biogenex) 
2. Secondary antibody 
 a. Enhancer (Biogenex secondary kit) 
 b. Streptavidin HRP (Biogenex secondary kit) 
3. Chromogen DAB (3-Diaminobenzidine Tetrahydrochloride)  
  
Procedure: 
Pretreatment of the slides: 
• The slides were first washed in tap water for few minutes.  
• They were then soaked in detergent solution for 1 hour. 
• After 1 hour, each slide was brushed individually using the detergent solution 
and were transferred to distilled water. 
• Slides were washed in two changes of distilled water. 
• The slides were then immersed in 1 N HCL (100 ml HCL in 900 ml distilled 
water) overnight. 
• The following day, slides were taken out of acid and washed in two changes of 
autoclaved distilled water. 
• All the slides were then transferred to slide trays, wrapped in aluminum foil 







Slides were first dipped in couplin jar containing acetone for 2 minutes 
 
Dipped in APES for 5 minutes 
 
Dipped in two changes of distilled water for 2 minutes each 
 
Slides were left to dry 
 
Preparation of sections:   
 After the slides were dry, tissue sections of 0.5 micron thickness were made in 
a rotary manual microtome. The ribbons of tissue section were transferred onto the 
APES coated slide from the tissue float bath such that two tissue bits come on to the 
slide with a gap in between. One of the tissue sections was labeled positive (P) and 
the other negative (N). 
 
Immunohistochemistry procedure: 
 The slides with tissue sections were treated with three changes of xylene to 
remove paraffin wax. They were put in descending grades of alcohol and then 
rehydrated with water. Then the slides were transferred to citrate buffer and 
autoclaved for antigen retrieval at 15 lbs pressure for 15 minutes. The slides were 
allowed to cool and then washed in cold phosphate buffer (PBS) solution for 5 
minutes. Slides were treated with 3% hydrogen peroxide for 10 minutes to quench 
endogenous peroxidase activity of cells that would otherwise result in non-specific 
staining. After blotting the excess, the slides were treated with protein block reagent 
for another 10 minutes. The slides were then wiped carefully without touching the 
9 
 
tissue section with gauze to remove excess protein bock reagent. Circles were drawn 
around the tissues, so that the antibodies added later on do not spread and are 
restricted to the circle. The primary antibody (p53; DO7) (Biogenex) was added only 
to P tissue on the slide and PBS was added to the N tissue to prevent drying. The 
petridish containing the slides was incubated at room temperature for 1 hour. For p63, 
primary antibody (A4A, Biogenex) was added to P tissue and incubated for 1 hour. 
The sections taken out were washed in three changes of cold PBS for 5 minutes each 
to remove the excess antibody. Then the slides were wiped carefully without touching 
the tissue section to remove excess PBS. Then a drop of enhancer from the secondary 
antibody kit (Biogenex) was added on both the sections and the slides were incubated 
for 20 minutes. Later slides were washed in three changes of cold PBS for 5 minutes 
each. The slides were wiped carefully without touching the tissue section to remove 
excess PBS. Then a drop of Streptavidin from the secondary antibody kit (Biogenex) 
was added on both the sections and the slides were incubated for 30 minutes. The 
sections were washed in 3 changes of cold PBS for 5 minutes each.  The slides were 
wiped carefully without touching the tissue section to remove excess PBS. Then a 
drop of freshly prepared DAB (3' Diaminobenzidine Tetrahydrochloride - a substrate 
chromogen) was added on both sections. Slides were washed in PBS to remove excess 
DAB and then counter stained with Hematoxylin. The slides were placed in a tray of 
tap water for 5 minutes for the process of blueing. Then the slides were transferred to 
70% alcohol, 100% alcohol and xylene. The tissue sections were mounted with DPX. 
Slides were then observed under the microscope. Throughout the procedure care was 






Oral squamous cell carcinoma (OSCC) tissue was used as a positive control. 
p53 and p63 staining in OSCC were used as a standard benchmark to evaluate the 
intensity of staining among the study groups.  
 
Criteria for evaluation of p53 and p63 staining: 
• Localization of stain – staining was limited only to basal layers of the 
epithelium or seen both in basal and supra basal layers. 
• Labelling index (LI) was calculated by dividing the number of positive cells 
by the total number of cells counted in the slide and expressed as percentage. 
A minimum of thousand cells was counted for each slide. 
                            Number of positive cells             
        LI  =      x 100    















IHC procedure flow chart: 
 
APES coated slides with paraffin embedded tissue 
 
Placed in xylene I (5 min) 
 
Placed in xylene II (5 min) 
 
Placed in xylene III (5 min) 
 
Placed in 100% isopropanol (5min) 
 
Placed in 70% isopropanol (5min) 
 
Washed in distilled water thrice (5 min each) 
 
Kept in citrate buffer, autoclaved and allowed to cool 
 
Washed in PBS (5 min) 
 










Primary antibody added and incubated (1 hour) 
 
Washed in PBS thrice (5 min each) 
 
Secondary antibody (Enhancer) (20 min) 
 
       Washed in PBS thrice (5 min each)    
      
Streptavidin HRP (30 min) 
 




       Washed in PBS thrice (5 min each) 
 
Stained with haematoxylin  
 
Washed in tap water (5 min) 
 




Placed in 100% isopropanol (1 min) 
 
Placed in xylene (1 dip) 
 
Slides were mounted using DPX 
 





Statistical analysis was done using SPSS software (version 11.0.5). p value less than 
0.05 was considered to be statistically significant. 
 
• Comparison of the mean age among the groups was done using ANOVA 
• Pearson’s Chi-square test was done to compare the distribution of gender and 
habits among the study groups. 
• Mean labeling index and localization of p53 and p63 was compared among the 
study groups using Kruskal-Wallis test 
• To compare the staining characteristics between p53 and p63 in each group, 



















 p53 is a tumor suppressor gene located on chromosome 17p13.1. The p53 
gene consists of 11 exons, of which the first one is non-coding. This gene encodes a 
protein of molecular weight 53 KD. The p53 protein is a transcription factor that 
enhances the rate of transcription of six or seven known genes8. 
 
p53 domains: Structure-Function relationships 
The human p53 protein contains 393 amino acids and has been divided 
structurally and functionally into four domains. 
1. The first 42 amino acids at the N-terminus constitute a transcriptional 
activation domain. This domain interacts with the basal transcriptional 
machinery for specific activation of certain genes. 
2. The central part of the protein consists of sequence-specific DNA-binding 
domain localized between amino acid residues 102 and 292. It is a protease-
resistant and independently folded domain containing Zn2+ ion that is required 
for its DNA-binding activity. 
3. The C-terminus consists of tetramerisation domain responsible for the 
formation of p53 tetramers, which is the most active form of p53 in 
transactivation.  
4. The C-terminus also contains a regulatory domain, which can negatively 
regulate the central DNA-binding domain by binding to it and thereby inhibit 






Activation of p53: Upstream events 
 p53 is involved in detection of DNA damage, after which it can stop the 
progression of cell cycle while the damage is repaired or can trigger apoptosis and 
death of the damaged cell. In this context, p53 acts as “molecular policeman” or 
“guardian of the genome”. In the absence of functional wild-type p53, the ‘guardian’ 
function is lost; cells accumulate genetic damage and show marked genetic 
instability11. 
  
 The p53 protein has the ability to sense different kinds of stress to which the 
cells are exposed such as, DNA damage caused by UV radiation, γ radiation and 
mutagenic chemicals. The cellular proteins like ATM (ataxia telengiectasia mutated) 
recognize damaged DNA and phosphorylate the p53 protein by interaction through 
their protein kinase domain. The phosphorylation results in a rapid increase in the 
levels of p53 in the cell and activation of p53 as a transcription factor. The p53 level 
increases because the half-life of protein is lengthened and also because the rate of 
translation of p53 mRNA is enhanced. To perform its function, the p53protein must, 
apart from being activated, be transported into the nucleus and also form tetrameric 
complexes with other p53 molecules. The activated p53 protein binds to specific 









Responses to activation of p53: Downstream events 
 The downstream events mediated by p53 take place by two major pathways: 
1. Cell cycle regulation: 
  Activated p53 induce the transcription of p21 and GADD45 (Growth Arrest 
and DNA Damage) genes. p21 functions by inactivating the cyclin D-CDK4 
complex, which is necessary for the progression of cell cycle through the S phase. 
p53-dependent transcription of p21 mediates cell cycle arrest in late G1 phase and 
allows enough time to repair the DNA damage. GADD45 gene encodes a protein 
involved in DNA repair. If the DNA damage is repaired successfully, p53 
activates MDM2, whose product binds to and degrades p53, thus relieving the cell 
cycle block. 
 
2. Regulation of apoptosis: 
 The p53 protein induces the activation of pro-apoptotic genes like Bax. Bax 







p53 mutations and cancer:  
 Mutation and subsequent inactivation of a tumor suppressor gene causes “loss 
of function”. However, tumor suppressor genes are most commonly recessive to the 
normal allele, meaning that if one allele is mutated its phenotype is not expressed as 
long as the other allele’s nature if of wild type.  The inheritance of one mutant p53 
allele predisposes individuals to develop malignant tumors because only one 
additional “hit” is needed to inactivate the second, normal allele. Such individuals, 
said to have “Li-Fraumeni syndrome”, have a 25-fold greater chance of developing a 
malignant tumor by age 50 than the general population. The spectrum of tumors that 
develop in patients with Li-Fraumeni syndrome is quite varied; the most common 
types of tumors are sarcomas, breast cancer, leukemia, brain tumors and carcinomas 
of the adrenal cortex12.  
 
 In most cases, the inactivating mutations affect both p53 alleles and are 
acquired in somatic cells. The most common type of mutation is the mis-sense 
mutation (where a change in one or more bases of a codon changes the affected codon 
into specifying a different amino acid), constituting up to 79% of all mutations. More 
than 90% of these mis-sense mutations in p53 reside in the DNA-binding domain and 
they fall into two classes. Mutations in amino acid residues such as R248 and R273 
results in defective contacts with DNA and loss of ability of p53 to act as a 
transcription factor. A second type of p53 mutation disrupts the structural basis of β 
sheet and loop-sheet helix motif, thereby altering the conformation of the protein.  
Since the mutations affect area of p53 protein outside the tetramerisation domain in 




 Mutations in p53 gene are found in up to 40-50% of squamous cell carcinomas 
of the head and neck region (SCCHN). Based on studies of SCCHN and cell lines, it 
has been suggested that after mutation of one p53 allele, the remaining wild type 
allele is deleted, and accordingly the mutant phenotype expressed. While the wild-
type p53 protein has a short half life (about 20 minutes), the mutant protein has a 
greatly enhanced stability, allowing for the immunohistochemical detection. 
However, the protein can also remain in the tissue for longer duration for certain 
reasons such as a defect in degradation pathway or by binding to other proteins. For 
example, p53 is known to bind to certain virus-encoded proteins like SV40 large T, 
which blocks its DNA binding activity and adenovirus E1B, which blocks its 
transcriptional activity. p53 also binds to HPV E6, which targets it for accelerated 
degradation10. 
 
p53 expression in oral precancer and cancer: 
 Kaur J, Chakravarti N, Mathur M et al (2004)13 studied the expression of 
p53 and retinoic acid receptor β (RAR β) proteins using IHC in 50 cases of OSF and 
30 histologically normal oral tissues. p53 immunostaining was detected in 48% 
(24/50) of OSF cases. Increased nuclear expression of p53 was predominantly limited 
to the basal layer of the epithelium. A significantly increased p53 expression and 
decreased RAR β expression were observed in OSF lesions when compared to normal 
oral mucosa. 36% (18/50) of OSF lesions demonstrated concomitant alterations in 
both these proteins, suggesting that alteration in p53 an RAR β expression might not 
be mutually exclusive events in OSF. Further, altered expression of either p53 or 
RAR β in majority of OSF lesions suggested their association with disease 
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pathogenesis and warranted follow-up to determine whether OSF lesions harboring 
concomitant alterations are at a high risk for malignant transformation. 
 
 Yamazaki Y, Chiba R, Hirai A et al (2003)14 analyzed p53 mutations in 121 
primary OSCC sample using PCR-single strand conformation polymorphism or yeast 
functional assay. p53 mutations were detected in 42% (51/121) cases of OSCC, of 
which 45 were point mutation, 4 frameshift deletions and 2 splice junctional 
mutations. Twenty three mutations were within zinc-binding domain and 28 
mutations were within DNA-binding surface regions. A significantly short survival 
was observed in patients whose tumors contained p53 mutations within the conserved 
regions compared to those with mutations outside these regions. The prognosis was 
significantly poor among the 28 patients with mutations affecting DNA-binding 
surface regions. The study strongly suggested that determining the specific mutational 
site by DNA sequencing was essential for evaluation of the nature of the mutated p53 
gene and the tumor characteristics. Additionally, p53 mutations within DNA-binding 
surface regions or conserved regions could be useful markers for predicting prognosis 
among OSCC. 
 
 Cruz I, Snijders PJF, Houten VV et al (2002)15 investigated for p53 protein 
expression by IHC in 55 samples of OSCC. Twenty two cases showed no p53 
staining, 12 showed less than 25% positive cells, 6 cases showed 25-50% positive 
cells, 3 cases showed 50-75% positive cells and 12 cases showed staining in almost 
all of the tumor cells. Ten out of 55 cases, including five p53 immunopositive and 
five p53 immunonegative cases were subjected to microdissection followed by 
sequence analysis for the detection of TP53 mutations. Paired IHC and sequence 
21 
 
analysis revealed that p53 immunoexpression in more than 25% of tumor cells was 
indicative of TP53 mutations. p53 immunoexpression in more than 25% of the 
neoplastic cells was significantly associated with smoking. The authors concluded 
that 25% p53 immunopositive cells appeared to be a good cut off value to predict 
TP53 mutations and p53 immunonegativity was not informative for TP53 mutations. 
 
 Van Houten VMM, Tabor MP, van den Brekel MWM et al (2002)16 
analyzed 50 head and neck SCC samples for the presence of p53 mutations by direct 
sequencing. 60% (30/50) of the samples showed a p53 mutation in the primary tumor. 
Histopathologically tumor free surgical margins of these 30 patients were analyzed 
for p53 mutation using the p53 plaque hybridization assay, of which 19 patients 
showed p53 mutated DNA in one or more additional margin samples.  IHC confirmed 
the presence of minimal residual cancer (MRC) in 12/19 mutated p53 positive cases. 
In 7/19 cases, p53 mutation was found in unresected dysplastic mucosal precursor 
lesions. The authors concluded that by using p53 mutations as a marker, both MRC 
and unresected mutated p53 positive mucosal precursor lesions were detected within 
surgical margins. Molecular assessment of surgical margins using p53 mutations 
enables the selection of head and neck SCC patients at high risk for tumor recurrence. 
 
 Shin DM, Charurul N, Lippman SM et al (2001)17 analyzed p53 protein 
expression using IHC in 48 SCC of the head neck region, 31 sites of normal 
epithelium adjacent to tumors, 24 sites of hyperplasia and 26 sites of dysplastic 
lesions. p53 protein was detected in 58% (28/48) of carcinomas, 19% (6/31) of 
normal epithelium adjacent to tumors, 24% (7/24) of hyperplasia and 46% (12/26) of 
dysplasias, but none of the normal control epithelium expressed detectable levels of 
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p53. The frequency of p53 expressing cells gradually increased from normal to 
hyperplasia, dysplasia and SCC. The authors also performed in situ hybridization to 
detect polysomies of chromosomes 17 and 9. The lesions with dysregulated p53 
expression showed nearly 2-3 fold increased levels of chromosomal polysomy. These 
findings suggested that altered p53 expression is associated with increased genetic 
instability in premalignant epithelium and acts as a driving force for increasing the 
rate of accumulation of genetic events in head and neck tumorigenesis. 
 
 Lingen MW, Chang KW, McMurray SJ et al (2000)18 investigated the 
status of p53 in patients with SCC of tongue with no known risk factors. 
Immunohistochemistry was used for the detection of p53 protein and single strand 
conformation polymorphism was used to identify mutations of the p53 gene in 21 
SCC specimens from patients less than 40 years of age. Nuclear staining for p53 was 
detected in 81% (17/21) of the SCC specimens. The pattern of overexpression of p53 
was associated with the histologic grade of the tumor. All the 15 cases of grade I and 
grade II tumors were positive for p53, while only 2 of the 6 grade III tumors were 
positive for p53. None of the patients demonstrated mutations in p53 gene. This 
analysis included the evaluation of exons 5-9; therefore, it is possible that a mutation 
in one of the other exons had occurred. The results suggested that altered p53 in 
OSCC from young individuals with no risk factors is due to different molecular 
mechanisms when compared to the altered p53 in typical cases of OSCC. 
 
 Cruz IB, Meijer CJLM, Snijders PJF et al (2000)19 used 42 samples of non-
malignant mucosa adjacent to OSCC, the respective carcinomas and six lymph node 
metastases to investigate for p53 protein expression by IHC. In 17% (7/42) of 
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specimens from non-malignant areas adjacent to OSCC, p53 expression was noted 
above the basal cell layer. Six of these were adjacent to carcinomas showing p53 
expression in more than 50% of the neoplastic cells. The majority of cases with supra 
basal p53 expression in the immediately adjacent non-malignant mucosa (86%) 
showed moderate or severe dysplasia in the same area. The lymph node metastases 
showed the same patterns of p53 expression as the carcinomas from which they were 
derived. Supra basal expression in the non-malignant mucosa was found only adjacent 
to p53 positive tumors, suggesting that p53 alterations occur early in carcinogenesis 
and that these alterations are maintained upon progression to overt malignancy. The 
authors concluded that p53 immunostaining in non-malignant mucosa of the resection 
margins of OSCC might be a valuable predictor for local recurrences and may 
therefore have implications for the management. 
 
 Shahnavaz SA, Regezi JA, Brdley G et al (2000)20 analyzed 24 samples 
from 10 patients with two or more distinct lesions from the same site in the oral cavity 
with the diagnosis of hyperkeratosis, epithelial dysplasia or SCC. The samples 
comprised of one hyperkeratosis, 12 dysplasias, 3 carcinomas in situ and 8 SCC. 
Standard IHC with DO7 monoclonal antibody was used to detect p53 protein and 
mutational analysis was performed using direct sequencing technique. Mutations were 
identified in 1 of 12 dysplasias, 2 of 3 carcinomas in situ and 6 of 8 carcinomas. Eight 
of these mutations were mis-sense and one occurred at a splice site. The 
overexpression of p53 protein was identified in 12 lesions and did not correlate with 
the gene status. In six of the eight patients who progressed from epithelial dysplasia or 
carcinoma in situ to carcinoma, p53 mutation was found only in carcinoma and not in 
any of the non-invasive lesions. This suggested that during oral carcinogenesis, p53 
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mutations probably occurred relatively late and were associated with transformation 
to the invasive phenotype. 
 
 Partridge M, Kiguwa S, Emilion G et al (1999)21 examined 45 cases of 
OSCC for the presence of p53 protein using IHC. These tumors were also screened by 
single strand conformation polymorphism for the presence of p53 mutations. High 
levels of p53 protein was detected in 25/45 cases and point mutations involving exons 
4-9 were seen in 11 cases of OSCC.  There was no relationship between tobacco use 
and detection of p53 by IHC, as 52% of non-smokers had p53 positive tumors 
compared with 50% of smokers. To examine loss of heterozygosity, PCR-RFLP 
analysis was performed and fraction allelic loss (FAL) score was calculated for each 
tumor. Tumors which were positive for p53 by IHC had a greater FAL score than 
cases which were negative by IHC. The authors also reported frequent detection of 
p53 by IHC in the absence of mutation, suggesting that in some cases, IHC might 
detect stabilized wild-type p53 as a consequence of ongoing DNA damage. 
 
 Chiang CP, Huang JS, Wang JT et al (1999)5 used anti-p53 antibodies to 
examine the expression of p53 protein in 81 cases of OSCC from patients who were 
areca quid chewers and/or tobacco smokers. Positive p53 nuclear staining was 
observed in 58% (47/81) of cases. p53 positivity was detected predominantly in the 
peripheral cells of the tumor nests as well as in the basal and para basal layers of the 
epithelium. p53 overexpression was higher in patients without areca quid chewing and 
tobacco smoking than in those with these habits. Kaplan-Meier analysis showed that 
the prognosis for p53 negative tumors was significantly better than that for patients 
with p53 positive tumors. A significant correlation was also observed between 
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positive lymph node status and poor prognosis. The results suggested that areca nut 
chewing or tobacco smoking may not play a role in p53 overexpression of OSCC. 
Furthermore, p53 overexpression may serve as an adjuvant marker of poor survival in 
patients with OSCC in Taiwan. 
 
 Murti PR, Warnakulasuriya KAAS, Johnson NW et al (1998)22 compared 
the p53 expression in archival tissues from 22 baseline biopsies of precancerous 
lesions that transformed to cancer in 4-25 years against that in 68 similar lesions that 
did not transform over the same time period. Twenty nine percent of precancerous 
lesions that transformed to cancer were p53 positive at baseline compared to 31% of 
the lesions that did not transform to malignancy. These results suggested that 
detection of p53 protein by IHC in biopsies of oral precancerous lesions had no 
significant relationship to their likely malignant transformation. Among 10 cases of 
malignant transformation that did not show p53 expression at baseline, nine 
developed p53 expression at the time of cancer formation. This suggests that p53 
overexpression peaks close to the time of transition from precancer to cancer rather 
than early in the natural history of oral precancer. 
 
 Trivedy C, Warnakulasuriya KAAS, Tavassoli M et al (1998)4 analyzed 21 
cases of OSF and 27 cases OSCC, of which 6 had arisen from OSF, to study the 
aberrations in structure and expression of p53 gene. The expression of p53 protein 
was detected by IHC using monoclonal antibody DO7 and PCR-SSCP (Polymerase 
chain reaction-Single strand conformation polymorphism) method was used for 
mutation analysis. Positive immunostaining was noted in 75% (15/21) of OSF 
specimens, 50% (3/6) of OSCC arising from OSF and 67% (14/21) of OSCC not 
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arising from OSF. In OSF, p53 protein was observed mainly in the basal layer of the 
epithelium. In OSCC specimens, positively stained cells were distributed widely in 
some cases and limited to a few foci in other cases.  Mutation in p53 or loss of 
heterozygosity was seen in 13/21 case of OSF and 15/27 cases of OSCC.  An 
increased tendency for cases with immunopositivity to harbor a mutation in p53 gene 
was noted in both OSF and OSCC. The results suggested that p53 mutation/protein 
stabilization may a play a role in the pathogenesis of OSF and its progression to 
OSCC. The authors consider it prudent to recommend p53 immunostaining of OSF 
biopsy specimens as a biomarker of DNA damage. 
 
 Warnakulasuriya KAAS, Tavassoli M, Johnson NW et al (1998)23 
performed immunohistochemical analysis of p53, p21 and p27 proteins in 24 cases of 
OSCC. Positive nuclear staining was detected in 10/24 OSCC, but none of the normal 
mucosa specimens showed p53 positivity. Heterogeneous expression of p21 and p72 
proteins were noted in 10/24 OSCC and 9/16 OSCC respectively. The expression of 
p21 and p27 did not correlate with p53 status. Eight OSCC specimens lacked the 
expression of both p21 and p27, but only two of these tumors over-expressed p53, 
suggesting that accumulation of p21/27 could be independent of the functional status 
of the p53 gene. The study supports the view that not all cell cycle regulators are 
affected in any one cancer and among other cellular factors, p27 may be reciprocally 
down-regulated when the p53 pathway is ineffective. 
 
 Kerdpon D, Rich AM & Reade PC (1997)24 studied 8 cases of normal oral 
mucosa, 50 cases of oral mucosal hyperplasia, 41 cases of oral dysplasia and 40 cases 
of OSCC for the expression of p53 protein. All cases of normal oral mucosa were 
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negative for p53. In hyperplasia, p53 staining was noted mainly in the basal and supra 
basal layers, with none of the cases having more than 50% of positive cells. When 
compared to hyperplasia, significantly more cases of dysplasia expressed p53 
staining. There was also a significant increase in the distribution pattern of positively 
stained cells from dysplasia to OSCC. When observed for periods of 21-80 months, 
none of the p53 negative cases progressed clinically, whereas for the 26 positive 
cases, 1/26 changed from mild to moderate dysplasia, 1/26 changed from moderate to 
severe dysplasia and 3/2 progressed from severe dysplasia to OSCC. Although the 
presence or absence of p53 staining could not be used to predict the outcome of 
potentially malignant oral mucosal lesions, the results indicated an involvement of 





 A recently discovered gene, p63 is mapped on chromosome 3q27-29 and is a 
member of the p53 gene family. The p63 gene is approximately 65 kilobase and 
contains 15 exons. The p63 gene gives rise to an array of multiple protein isoforms 
due to differential mRNA splicing and alternative promoter usage. The p63 gene 
undergo multiple C-terminal splicing, but among the high number of spliced isoforms 
found at the RNA level, 3 of them are consistently found at the protein level. The 3 
spliced forms of p63 produced are termed α (full structure), β (splicing of exon 13) 
and γ (splicing from exons 10 to 15).  
 
 The expression of p63 gene is regulated by the occurrence of two promoters 
that leads to the production of 2 different classes of proteins. The P1 promoter is 
located in the 5’ untranslating region (UTR) of a non-coding exon 1 and leads to 
isoforms showing N-terminal transactivation domain (TAp63). The P2 promoter is 
located within the 23-kilobase-spanning intron 3 and encodes isoforms lacking the N-
terminal transactivation domain (ΔNp63). The TA p63 group (comprising of α, β and 
γ isoforms) shows p53-like activities such as inducing cell-cycle arrest and apoptosis. 
The second group (ΔNp63 in α, β and γ isoforms) acts in a dominant negative fashion, 
inhibiting the transactivation activity of both TAp63 and p53. As a result, the TAp63 
protein favors cell differentiation, while ΔNp63 favors cell proliferation25,26. 
 
 p63 has an important role in the process of proliferation and/or differentiation 
of epithelial tissues including skin, breast and prostrate. The p63 gene also plays an 
essential role in the proliferation of limb and craniofacial structures during 
embryogenesis. Studies with murine model have revealed that p63-knockout mice are 
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born alive but they display severe deformation of limbs and profound defects in 
craniofacial development, as well as in differentiation of tissues with stratified 
epithelium including skin, oral cavity, esophagus, breast and prostrate. A similar 
pattern was observed in patients with ectrodactyly, ectodermal dysplasia and facial 
clefts (EEC) syndrome, an autosomal dominant disorder, where patients are found to 
have dominant heterozygous p63 mutations. 
 
 An experimental examination by the genetic elimination of p63 disclosed that 
it plays an essential role in epithelial development to maintain keratinocytes stem 
cells. This may be of practical importance for studies of epithelial tumorigenesis 
because it is thought that stem cells are involved in the formation of malignant 
tumors. Among the various isoforms, normal human keratinocytes express mainly the 
truncated dominant negative p63 isoforms during development. It has been reported 
that these ΔNp63-encoding transcripts are down-regulated during the irreversible 
growth arrest and differentiation of human keratinocytes. The overexpression of p63 
has been noted in SCC of the head and neck region and this has been attributed to 
increased p63 gene copy number27,28.    
  
p63 expression in oral precancer and cancer: 
 de Oliveira LR, Ribeiro-Silva A & Zucoloto S (2007)29 studied paraffin-
embedded sections from 106 OSCC patients for the expression of p63 and p53 using 
immunohistochemistry (IHC). p63 immunoreactivity was found in 87.8% (93/106) of 
the tumors, while p53 immunoreactivity was found in 52.8% (56/106) of the tumors. 
p63 expression was noted predominantly in well and moderately differentiated 
tumors, but absent in keratin pearl areas. The cases with lower intensity of p63 
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expression showed a higher number of metastasis than those with strong 
immunoexpression. A significant association was found between the intensity of p63 
staining and increased odds of overall survival. The p53 positive cases showed a 
higher metastasis rate (78.6%) compared with p53 negative cases. The patients with 
negative p53 expression had a better prognosis than those with positive p53 
expression and this was statistically significant. The authors concluded that p53 
overexpression and decreased intensity of p63 immunostaining was associated with 
metastases and correlated with poor outcome. 
 
 Haniffa AM, Saitoh M, Abiko Y et al (2007)30 investigated the expression 
pattern of p63 using IHC in 30 cases of SCC, 10 cases of epithelial dysplasia and 12 
cases of oral submucous fibrosis (OSF). In normal oral epithelium, p63 positivity was 
noted in the nuclei of some of the basal cells and focally in para basal layer. In SCC, 
p63 positivity was observed mainly in the peripheral cells of tumor nests. In epithelial 
dysplasia, staining was predominantly seen in the upper spinous layers. The positivity 
for p63 staining was increased in epithelial dysplasia when compared to normal oral 
epithelium. In OSF, the p63 staining was wider and more intense than in normal and 
dysplastic epithelium. OSF showed a significantly higher percentage of positive cells 
than dysplastic epithelium or SCC. The authors suggested that p63 might play an 
oncogenic role in oral carcinogenesis through the expression of wild type forms rather 
than acting as a tumor suppressor via mutant forms. The disruption of the normal 
function of p53 by mutation might result in a compensatory up-regulation of p63. A 
higher frequency of p53 mutations in OSF might have led to the higher percentage of 




 Takeda T, Sugihara K, Hirayama Y et al (2006)2 studied the expression of 
p63 and ki-67 proteins using IHC in 10 normal oral mucosa, 10 hyperplasia, 10 mild 
dysplasia, 10 moderate dysplasia, 13 severe dysplasia, 10 carcinoma in-situ and 9 
two-phase dysplasia. In the basal layer, p63 labelling index decreased from normal 
oral mucosa to carcinoma in situ, whereas in the supra basal layers, labelling index 
increased with the severity of dysplasia. ki-67 labelling index in the basal and supra 
basal layers increased according to the grade of dysplasia. The decrease of p63 
labelling index in the basal layer of epithelial dysplasias suggested an alteration of 
stem cell function and the stem cells could be replaced by proliferating cells as 
demonstrated by positive ki-67. The authors concluded that the architectural 
disorganization of proliferating cells and stem cells in oral epithelium could be a 
useful index to estimate the grading of epithelial dysplasias if added to 
histomorphological examinations in H & E sections. 
 
 Kovesi G & Szende B (2006)31 determined the expression of p63, cyclin D 
and p27 using IHC in 18 samples taken from homogenous leukoplakia, nodular 
leukoplakia and erythroleukoplakia. Immunoexpression of p63 appeared 
predominantly in the para basal and middle spinous layers. The p63 index was 10% in 
homogenous leukoplakia, 5% in nodular leukoplakia and 20% in erythroleukoplakia. 
The authors suggested that decrease in p63 expression was found in nodular 
leukoplakia as a part of a defense mechanism against malignant transformation. In 
erythroleukoplakia this mechanism appears to fail because the expression of p63 was 
increased significantly. The increase in p63 as well as cyclin D and decrease in p27 
expression correlated with the severity of leukoplakia and hence the authors 
concluded by pointing out the possibility that immunohistochemical demonstration of 
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these gene products might be a useful tool for a more precise prognosis of oral 
leukoplakia.  
 
 Chen Y-K, Hsue S-S & Lin L-M (2005)7 evaluated the expression of p63 
protein using immunohistochemistry in 90 samples of epithelial dysplasia (30 cases of 
mild, 30 moderate and 30 severe dysplasia), 15 samples of hyperplastic oral mucosa 
and 15 cases of normal oral mucosa. In normal buccal mucosa specimens, p63 nuclear 
staining was predominantly seen in the basal layer of epithelium and focally in para 
basal layers. In hyperplastic oral epithelium, staining was detected chiefly in basal 
cells and occasionally in cells above the basal layer. In mild epithelial dysplasia, p63 
staining was seen up to the middle spinous layer, whereas in moderate and severe 
dysplasias, the full thickness of the epithelium showed positive immunostaining. 
Furthermore, in 5 years follow-up, 16.7% (5/30) of moderate dysplasia and 30% 
(9/30) of severe dysplasia with positive p63 staining have undergone malignant 
transformation to squamous cell carcinoma. 
  
 RT-PCR was also done to detect p63 mRNA in 4 samples of mild and 
moderate dysplasia, 5 samples of severe dysplasia, 5 samples of hyperplastic 
epithelium and 5 normal mucosa. ΔNp63 mRNA was detected as a band 
corresponding to a 681-bp PCR product for all the specimens, whereas expression of 
TA (Transactivation) isotype was not detected in any of the specimen. 
  
The authors concluded by suggesting that the overexpressed p63 proteins 
might exert an alterative mechanism to overcome p53 tumor suppressor function and 
hence induce clonal expansion of the dysplastic keratinocytes. Therefore, p63-stained 
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keratinocytes could be important in neoplastic transformation of the squamous cell, 
favoring neoplastic proliferation and anti-differentiation effect. 
  
 Muzio LL, Santarelli A, Caltabiano et al (2005)32 studied p63 expression in 
94 samples of OSCC and 10 cases of normal oral mucosa using IHC. Normal oral 
mucosa showed 10% of stained cells, with the immunostaining localized to basal and 
para basal layers. 5.3% of OSCC showed less than 10% of positive tumor cells, 35% 
had 10-30% of positive tumor cells, 38% of the cases had 30-50% of positive tumor 
cells, while 21% of OSCC had more than 50% positive tumor cells. There was a 
statistically significant increase in the expression of p63 staining in poorly 
differentiated OSCC when compared to well and moderately differentiated OSCC. 
Survival analysis revealed that the patients with increased p63 expression had poor 
survival rates than those with reduced p63 expression. The authors suggested that p63 
expression may be useful to identify cases of OSCC with more aggressive and 
invasive phenotype providing novel prognostic information on individual patient 
survival. 
 
 Mognetti B, Trione E, Corvetti G et al (2005)33 evaluated ΔNp63 mRNA 
expression using RT-PCR in the surgical margins of a case of SCC of the floor of the 
mouth in a 68 year old male patient. A sample of healthy contralateral mucosa served 
as a baseline control. Routine histopathological evaluation revealed clear margins, 
while ΔNp63 mRNA expression in one of the margins was 6.6 folds higher than the 
baseline level, and comparable to that measured in the tumor. In the same margin, a 
more accurate and time consuming histological analysis on serial sections revealed 
the presence of neoplastic cells. The authors therefore considered this technique as a 
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good method to screen the clear surgical margins to support the classic histologic 
analysis. 
 
 Bortoluzzi MC, Yurgel LS, Dekker N et al (2004)34 assessed the expression 
of p63 protein in 10 cases of hyperkeratosis, 9 cases of mild dysplasia, 11 moderate 
dysplasia, 10 severe dysplasia/in situ carcinoma, 22 SCC and 5 normal mucosa using 
IHC. The normal mucosa showed intense p63 staining of basal, para basal and supra 
basal cells that gradually decreased at the mid-level of the epithelium. p63 staining 
was also noted in the basal and supra basal keratinocytes of hyperkeratosis and 
epithelial dysplasia specimens. The number of p63 positive cells was significantly 
greater in epithelial dysplasias when compared to hyperkeratosis. The majority of 
tumor cells stained positive for p63 and a significantly greater number of positive 
cells was found in SCC than that observed in epithelial dysplasias.  Moderately 
differentiated SCC had significantly greater number of positive cells than well 
differentiated SCC. As p63 was expressed in nondiagnostic patterns in a variety of 
oral lesions, the authors concluded that p63 expression in oral keratinocytes might be 
more closely related to stem cell maintenance and cell differentiation than 
tumorigenesis. 
 
 Chen Y-K, Huse S-S & Lin L-M (2004)35 investigated the differential 
expression of p63, p53 and p73 protein and mRNA for DMBA-induced hamster 
buccal pouch squamous cell carcinomas (SCC) using IHC and RT-PCR respectively. 
Using IHC, nuclear staining of p63 protein was noted for all of the 20 hamster buccal-
pouch tissue specimens treated with DMBA, as well as for all the untreated and 
mineral oil treated buccal pouch tissue specimens. p53 and p73 proteins were detected 
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for a subset of hamster buccal pouch tissue specimens treated with DMBA and were 
not noted in the untreated and mineral oil treated pouch mucosa. For the carcinoma 
samples, both p63 and p73 immunoreactivity was chiefly observed in the less 
differentiated cells located at the periphery of carcinomatous clusters.  
  
Using RT-PCR, ΔNp63 mRNA was detected for all the 20 hamster buccal 
pouch tissue specimens treated with DMBA, all mineral oil treated and untreated 
buccal pouch specimens, whereas expression of Tap63 was not detected in any of the 
specimen. Differential expression of p53, p63 and p73 protein in experimental group 
was as follows: p63+/p73+/p53+ (70%), p63+/p73+/p53- (10%) and p63+/p73-/p53- 
(20%). Additionally, significant correlation between p63, p73 and p53 expression was 
demonstrated for the hamster buccal pouch carcinoma samples. These results 
indicated that both p63 and p73 may be involved in the development of chemically 
induced hamster buccal pouch carcinomas, in concert with p53. 
 
 Foschini MP, Gaiba A, Cocchi R et al (2004)6 investigated 39 samples of 
OSCC for the presence of p63 protein and mRNA using immunohistochemistry and 
RT-PCR and compared it with the non-neoplastic mucosa adjacent to the tumor. IHC 
revealed that percentage of positive cells increased from normal to neoplastic mucosa 
and p63 positive cells were predominantly seen in the basaloid cells present at the 
periphery of the neoplastic nests. The percentage of p63 positive cells was higher in 
poorly differentiated OSCC than in well differentiated OSCC. In the non-neoplastic 
mucosa, p63 positivity was confined to the basal and para basal layers of 
keratinocytes, with positive cells never exceeding 10% of the keratinocytes. RT-PCR 
revealed that ΔNp63 was the most frequently expressed isoform, being present in 
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97.4% (38/39) of the cases. The truncated isoforms ΔNp73L and Δ4TAp63 were more 
frequently expressed in patients presenting with lymph node metastases. The authors 
concluded that an impaired expression of the p63 isoforms might favor cell 
proliferation and indirectly enhance the metastasizing capacity of OSCC. 
 
 Thurfjell N, Coates PJ, Uusitalo T et al (2004)36 used quantitative real-time 
RT-PCR to study p63 isoforms in 13 cases of SCC of the head and neck. Both the 
ΔNp63 and p63β isoforms were significantly more expressed in tumors compared to 
normal tissue from the dame patient. Eleven of the 13 tumors had diagnostic biopsies 
available for immunohistochemical analysis. All 11 were positive for p63 antibody 
and the staining was found throughout the tumors, with the exception of foci of more 
differentiated islands of keratinizing cells.  
  
Matched pairs of samples from smokers and non-smokers were analyzed for 
expression of p63 mRNA and protein by RT-PCR and IHC respectively. As with the 
tumor samples, ΔN isoform predominated, although low levels of TA isoform could 
also be detected. Although the highest levels of p63 were seen in individuals with a 
history of smoking, no significant difference in p63 expression was seen between 
smokers and non-smokers, indicating that p63 might not be involved in the response 
to tobacco-derived genotoxic agents. The results suggested that SCC of head and neck 
maintain expression of high levels of ΔNp63 in combination with varying levels of 
other isoforms, and this expression significantly influences the differentiation status 




 Chen YK, Hsue SS & Lin LM (2003)37 performed immunohistochemical 
analysis to study the differential expression of p63, p53 and p73 proteins in 40 
samples of well differentiated buccal SCC and compared it with 10 specimens of 
normal buccal mucosa. Nuclear staining of p63 and p73 were noted in the basal layers 
of the normal buccal mucosa, while p53 expression was not noted in the normal 
epithelium. In the carcinoma samples, both p63 and p73 immunoreactivity were 
chiefly observed for the less-differentiated cells located at the periphery of 
carcinomatous clusters. For p53 protein, positive staining was demonstrated for some 
cells in the upper layers of tumor islands. Differential expression of p63, p73 and p53 
proteins in carcinomas were: p63+/p73+/p53+ (70%; n=28/40), p63+/p73+/p53- 
(10%; n=4/40) and p63+/p73-/p53- (20%; n=8/40). In this study, p63 and p73 were 
frequently expressed simultaneously and were positively correlated with each other, 
suggesting a synergistic effect with respect to tumor development in the oral cavity.  
 
 Chen YK, Hsue SS & Lin LM (2003)38 analyzed p63 expression in DMBA 
induced hamster buccal pouch SCC using immunohistochemical studies. For all the 
untreated and mineral oil treated pouch mucosa, nuclear positivity for p63 was mainly 
observed in basal/para basal cell layers, whereas, positive staining was observed 
throughout the whole epithelial layer in DMBA treated pouch mucosa specimens. For 
carcinoma specimens, p63 staining was more uniform and homogenous in less 
differentiated tumor areas, while expression was noted mainly in the peripheral cells 
of tumor nests in well differentiated tumors. The authors suggested that p63 
expression in DMBA induced pouch carcinogenesis will block the growth inhibition 
and apoptosis-indication activities of p53, and thus, may help maintain the 
proliferative capacity of progenitor cells in hamster buccal pouch mucosa. 
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 Choi HR, Batsakis JG, Zhan F et al (2002)39 performed 
immunohistochemical analysis of p63, p73 and p53 proteins in 38 samples of head 
and neck carcinoma, 16 dysplastic lesions and 25 samples of histologically normal 
squamous epithelium. In normal epithelia, nuclear p63 staining was noted in the basal 
and para basal layers of the epithelium in all the specimens. p63 positivity increased 
with histologic progression in all 16 dysplasias. In carcinomas, p63 staining was more 
uniform and intense than p53 and p73 in 94.7% (n=36/38) of the samples. In well-
differentiated tumor areas, p63 was noted mainly in the peripheral cells of tumor nests 
and generally absent in terminally differentiated cells. In normal mucosa, p53 
expression was focal to patchy and was confined wo the basal/parabasal layers. In 
dysplastic lesions, p53 positive cells increased in number and intensity with 
progression of dysplasia in 68.7% (n=11/16) of cases. Of the 38 carcinomas, p53 
staining was noted in 52.6% of the samples. A significant association between p63 
and p73 expression was observed, but no correlation between p63 or p73 with p53 
was noted. The study suggested a synergistic cooperation of p63 and p73 in the early 
development of dysplasias and/or a compensatory up-regulation in response to p53 
alteration. 
 
p63 expression in other oral lesions: 
 Ebrahimi M, Wahlin Y-B, Coates PJ et al (2007)40 analyzed the sera from 
20 consecutive patients diagnosed with oral lichen planus (OLP) for the presence of 
antibodies against p63 and p73 using western blotting. The sera from two OLP 
patients reacted with p63 proteins. Both of these patients reacted with all six p63 
isoforms with varying intensity. Sera from one of these two OLP patients also reacted 
with the four p73 isoforms. The strong reaction seen against p63 isoforms could be an 
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indication that the epithelial cells in these lesions could not differentiate normally and 
thus are considered foreign to the body and evoke an immune response. Further, 
patients with a milder disease or disease of shorter duration could have antibodies 
against p63 at levels too low to be detected by Western blotting.  
 
 Ebrahimi M, Wahlin Y-B, Coates PJ et al (2006)41 studied the expression of 
p63 and p53 proteins using IHC in 46 samples of OLP and 8 samples of graft vs host 
disease (GVHD) and compared it with 16 normal oral mucosa and 12 samples of SCC 
of the head and neck region. In normal oral mucosa only a few cells in the basal cell 
layer expressed p53, whereas OLP and GVHD samples showed increased expression 
of p53. A decreased expression of all p63 isoforms were seen in OLP and GVHD 
when compared to normal oral mucosa. In SCC of the head and neck region, ΔNp63 
proteins were detected at a higher level compared with normal mucosa. It is likely that 
decreased p63 an increased p53 proteins inn OLP and GVHD might represent a 
protective response to increased levels of DNA damage resulting from chronic 
inflammation. The coordinated stabilization of p53 and decreased expression of p63 
enables apoptosis of epithelial cells to remove damaged cells with the potential for 
malignancy. In SCC, increased p63 expression might provide an advantage to the 
initiated cells exposed to further damage by allowing their continued survival and 
thereby increasing the likelihood of accumulating the successive oncogenic 
alterations. 
 
 Kumamoto H, Ohki K & Ooya K (2005)42 evaluated tissue specimens of 9 
tooth germs and 48 benign and 5 malignant ameloblastomas for the 
immunohistochemical expression of p63 protein. In tooth germs, expression of p63 
was found in most cells of the cells of  inner and outer enamel epithelium and in 
40 
 
fewer cells of stratum intermedium and stellate reticulum. Ameloblastomas showed 
p63 reactivity predominantly in the peripheral columnar or cuboidal cells and only in 
fewer central polyhedral cells. Desmoplastic ameloblastomas demonstrated 
significantly higher p63 expression when compared to acanthomatous and granular 
cell ameloblastomas. P63 expression in ameloblastic carcinomas was significantly 
higher than in metastasizing ameloblastomas. RT-PCR done for identification of p63 
mRNA revealed that mRNA transcripts for ΔNp63 were detected in all 
ameloblastomas and inn tooth germs. The results suggested that p63 expression is 
associated with proliferation of neoplastic odontogenic epithelial cells and also might 
be involved in malignant transformation of odontogenic epithelium. 
 
 Edwards PC, Bhuiya T, Kelsch RD et al (2004)43 determined the expression 
of p63 immunoreactivity in 17 samples of polymorphous low grade adenocarcinoma 
(PLGA), 15 adenoid cystic carcinomas (ACC), 6 canalicular adenoma and 11 basal 
cell adenoma. Nuclear p63 reactivity was uniformly positive in PLGA, suggesting 
that the neoplastic cells in PLGA might represent a population either of p63 positive 
epithelial stem/reserve cells similar to the basal cells of stratified epithelium, or of 
modified myoepithelial cells. Positive reactivity was also identified in 87% of ACC, 
primarily in the nonluminal myoepithelial-like cells surrounding luminal cells. No 
p63 staining was seen in canalicular adenoma, whereas variable staining was noted in 
basal cell adenoma. All basal adenoma of parotid gland origin stained strongly 
positive for p63, but none of the basal cell adenoma of the upper lip stained for p63. 
The authors concluded that p63 was neither an ideal marker for distinguishing 
between PLGA and ACC, nor useful in separating canalicular adenoma from basal 




Patient characteristics:  
Twenty cases of OSCC (Group I), 20 cases of leukoplakia (Group II), 20 cases 
of OSF (Group III) and 10 histologically normal oral mucosal samples (Group IV) 
were assayed for p53 and p63 proteins using immunohistochemistry.  
 
The patients’ ages ranged from 38 to 85 years (mean of 55.2 years) in group I, 
from 30 to 73 years (mean of 43.6 years) in group II,  from 23 to 51 years (mean of 
36.4 years) in group III  and from 19 to 42 years (mean of 29.5 years ) in group IV  
(Table 1, Graph 1). Of the 20 patients in group I, 16 (80%) were men and 4 (20%) 
were women. In group II, all 20 (100%) were men. In group III, 19 (95%) were men 
and only one (5%) was a woman, whereas in group IV, 4 (40%) were men and 6 
(60%) were women (Table 2, Graph 2). All the samples in group I, II, III and IV 
were taken from the buccal mucosa. 
 
The oral habits of the patients in the study group were categorized as smoking 
or chewing. In group I, 4 (20%) patients had smoking habit, 11 (55%) had chewing 
habit, while 5 (25%) had both smoking and chewing habits. In group II, 9 (45%) 
patients had smoking habit, 5 (25%) had chewing and 6 (30%) had both smoking and 
chewing habits. In group III, 17 (85%) had chewing habit, whereas 3 (15%) had both 
chewing and smoking habits. All the patients in group III had the habit of chewing 
pan masala. In group IV, none of the patients had any oral habits (Table 3, Graph 3). 
Of the 20 cases in group I with features of squamous cell carcinoma 
histologically, 14 (70%) were well differentiated, 4 (20%) moderately differentiated 




All the cases in group II showed features of epithelial dysplasia histologically, 
with 9 (45%) mild dysplasia, 7 (35%) moderate dysplasia and 4 (20%) severe 
dysplasia (Table 5, Graph 5). 
 
Distribution of p53 staining among study groups: 
p53 immunostaining revealed positivity in all the cases of group I, II and III 
(Group I: Figures 8,9; Group II: Figures 16,17; Group III: Figures 24,25). In 
group IV, only 3 (30%) of the cases showed positive staining for p53, while the 
remaining 7 (70%) cases were negative for p53. Figures 32 and 33 are representative 
pictures of p53 staining in group IV.  
 
Mean labeling index (LI) was calculated for all the four study groups and was 
expressed as percentage of positive cells. The mean LI for group I, II, III and IV were 
56.9 ± 21.3, 37.6 ± 12.6, 34.6 ± 8.7 and 15.1 ± 9 respectively; the difference in mean 
LI among the groups was statistically significant (p=0.00) (Table 6, Graph 6). There 
was statistically significant difference in the mean LI of p53 between group I and 
group II (p=0.00), between group I and group III (p=0.00) and between group I and 
group IV (p=0.00). Mean LI of p53 was found to be significantly different between 
group II and group IV (p=0.00) and between group III and IV (p=0.00). 
 
p53 immunostaining was observed only in the basal layer of the epithelium or 
both in the basal and supra basal layers of the epithelium in group II, III and IV. Four 
(20%) cases in group II had basal staining and 16 (80%) had both basal and supra 
basal staining. In group III, 8 (40%) of the cases showed basal stain, while 12 (60%) 
showed both basal and supra basal staining. Of the 3 positive cases in group IV, 2 
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(20%) had basal stain, whereas one (10%) case had both basal and supra basal stain. 
The tissue localization of p53 staining was significantly different among the 3 study 
groups (p=0.00) (Table 7, Graph 7). There was statistically significant difference in 
the localization of p53 stain between group II and group IV (p=0.01) and between 
group III and IV (p=0.00). 
 
Distribution of p63 staining among study groups: 
p63 immunostaining revealed positivity in all the cases of group I, II, III and 
IV. (Group I: Figures 12,13; Group II: Figures 20,21; Group III: Figures 28,29; 
Group IV: Figures 36,37). The mean LI for group I, II, III and IV were 56.8 ± 19.6, 
42.3 ± 10.5, 32.8 ± 12.1 and 26.4 ± 9.4 respectively and the difference was 
statistically significant (p=0.00) (Table 8, Graph 8). There was statistically 
significant difference in the mean LI between group I and group II (p=0.02), between 
group I and group III (p=0.00) and also between group I and group IV (p=0.00). Mean 
LI of p63 was found to be significantly different between group II and III (p=0.01) 
and between group II and group IV (p=0.00). 
 
Two (10%) cases in group II had only basal staining and 18 (90%) had both 
basal and supra basal staining. In group III, 6 (30%) cases showed basal stain, while 
14 (70%) showed both basal and supra basal staining. In group IV, 5 (50%) cases had 
basal stain, whereas the remaining 5 (50%) had both basal and supra basal stain. The 
tissue localization of p63 staining was not statistically significant among the 3 study 





Correlation between p53 and p63:  
 Pearson’s correlation analysis of p53 and p63 mean LI showed statistically 
significant positive correlation in OSCC (r=0.72) (p=0.00) and OSF (r=0.60) 
(p=0.00). Analysis also showed positive correlation between p53 and p63 in 
leukoplakia (r=0.28) and normal samples (r=0.45), but the positive correlation did not 






OSCC is considered to develop through a multistep process of accumulations 
of genetic mutations related to cell proliferation, differentiation and apoptosis. 
Mutations in the p53 gene are the most common genetic abnormality found in 40-50% 
of SCC of head and neck9. p63 gene, a member of p53 gene family, has a remarkable 
structural similarity to p53 and is responsible for the transactivation of 6 isoforms. 
Three isoforms (TAp63α, TAp63β, TAp63η) contain an N-terminal transactivation 
domain (TA) and can induce apoptosis. The other 3 isoforms (∆Np63α, ∆Np63β, 
∆Np63η), lack the TA domain and may function by inhibiting the transactivation 
functions of p53 and TAp63 proteins, and thus act as oncoproteins34. 
 p63 protein is known to play an essential role in epithelial development and 
proliferation of limb and craniofacial structures. p63 expression has been described in 
head and neck tumor of squamous lineage, suggesting that p63 overexpression may 
play a role in oncogenesis of these tumors34.  
Strikingly, squamous cell carcinoma of skin and oral cavity as well as the oral 
epithelial dysplastic lesions produce high levels of ∆Np63mRNA7,35. The most 
commonly used clone of p63, the 4A4 antibody does not discriminate the different 
isoforms of p636. However, the presence of TAp63 mRNA in skeletal muscle, in the 
absence of staining with 4A4 antibody, has been reported, indicating that this 
antibody may not identify all p63 isoforms by IHC27. 
  In the present study we have examined the expression of p53 and p63 
proteins in OSCC, leukoplakia and OSF samples and compared their expression with 







 OSCC is a malignancy commonly encountered in the older age group between 
50 - 70 years of age and rarely in patients younger than 40 years3. In a study by 
Mehrothra et al (2003), 7.6% of the patients with OSCC were between 30 to 40 
years44. In our study the age of the patients with OSCC ranged from 38 to 85 years 
with a mean age of 55.2 years. 
 Lumerman et al had examined 308 cases of leukoplakia and had shown that 
the average age of presentation was 59.3 years45. Studies by Saito et al have shown 
that the mean age for patients with leukoplakia was 54 years46. In our study, the 
minimum age of presentation for leukoplakia was 30 years and the maximum age was 
73 years with a mean of 43.6 years. 
 Ranganathan et al reported that the youngest and oldest age of occurrence of 
OSF was 16 years and 57 years respectively, with a mean age of 32.4 years47. In our 
study, the age of presentation for OSF ranged from 23 to 51 years, the mean age being 
36.4 years.  
 OSCC has been shown to exhibit gender predilection, with males being more 
commonly affected3.  The male to female ratio recorded by Mehrothra et al (2003) 
was 3.27:144. In our study 80% of the OSCC patients were males. This may be due to 
the reason that more number of males have the habit of smoking tobacco than 
females3. 
 Neville et al had reported a strong male predilection of 70% for oral 
leukoplakia, while Lumerman et al had shown that 52.8% of the patients in their 
study were males3,45. In our study all the patients with leukoplakia were males. 
47 
 
 Our study showed a high preponderance of OSF in males (95%), similar to the 
study done by Ranganathan et al who had examined 185 patients with OSF and had 
given a male to female ratio of 9.9:147. 
 The use of tobacco in either smoked (cigarettes, beedi, cigar, pipes) or chewed 
form is considered to be the most common factor associated with the etiology of 
OSCC48. In the study conducted by Mehrothra et al, 78.6% of OSCC patients were 
tobacco users in chewing or smoking form44. In the present study, 20% of OSCC 
patients were smokers, 55% chewers and 25% had both smoking and chewing habit. 
 Out of 20 patients with leukoplakia in our study, 45% of them had the habit of 
smoking tobacco, 25% were chewers and 30% had both chewing and smoking habit. 
This is in agreement with the report by Bouquot et al who related tobacco smoking 
with leukoplakia and reported that 66% of the patients with leukoplakia were 
smokers49. 
 Areca nut is considered to be the main etiological factor for the development 
of OSF. In vitro studies on human fibroblasts have shown that arecoline and 
arecaidine, the alkaloids present in areca nut, causes fibroblast proliferation and 
stimulation of collagen synthesis50. In our study, all the 20 patients with OSF had the 
habit of chewing pan masala (powdered areca nut with additives, flavoring agents and 
tobacco). These findings were consistent with that of Ranganathan et al, who 
reported that the prevalence of chewing pan masala was more in the males than in 
females47.  
 
p53 staining characteristics: 
  Our study showed p53 immunoexpression in 100% of OSCC, leukoplakia and 
OSF samples.  p53 immunoexpression in OSCC as reported by Cruz et al (2000), 
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Trivedy et al (1998) and in the study done by Partrige et al (1999) ranged from 52-
62%19,4,21. Kerdpon et al (1997) reported positive p53 staining in 94% of OSCC and 
85% of oral epithelial dysplasias24. Expression of p53 protein has been reported in 10-
50% of oral leukoplakia cases showing features of epithelial dysplasia 
histologically14,20. Kaur et al (2004) observed p53 expression in 48% of OSF 
samples13. Trivedy et al (1998) reported p53 immunoexpression in 75% (15/20) of 
OSF samples4. 
 70% of normal oral mucosa samples in the present study were negative for 
p53 staining, while 30% showed positive expression. This is in agreement with 
studies by Yanamoto et al (2002) and Kaur et al (2004), who reported 20% and 10% 
positivity for p53 in normal mucosa respectively51,13. The detection of p53 in normal 
epithelium has been attributed to the physiological stabilization of the wild type p53 
due to genotoxic stress caused by UV radiation, hypoxia and viral proteins, which 
might lead to increased half life of p53 protein and therefore detection by IHC11,13,19. 
In contrast, Kerdpon et al (1997) in their study found that all cases of  normal oral 
mucosa were p53 negative24.  
The mean LI was significantly higher in OSCC (56.9 ± 21.3), leukoplakia 
(37.6 ± 12.6) and OSF (34.6 ± 8.7) when compared to normal mucosa (15.1 ± 9) 
(p=0.00; p=0.00; p=0.00). These results are similar to the study by Kerdpon et al 
(1997) who showed that p53 expression increased from normal to hyperplasia to 
dysplasia to OSCC24. 
 In our study, p53 immunostaining was localized to both basal and supra basal 
layers of the epithelium in 80% of leukoplakia and 60% of OSF samples. Nylander et 
al stated that the expression of p53 stain in the supra basal layers was an indication of 
malignant development in oral premalignant lesions10. Cruz et al (1998) observed 
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p53 expression in supra basal cell layer of 25% of premalignant lesions. They 
demonstrated that p53 supra basal expression was significantly associated with 
development of carcinoma. They also stated that this pattern of p53 expression 
explained the presence of proliferating cells with DNA damage in the superficial 
compartments of the epithelium, especially in dysplasia. These authors suggested that 
p53 protein detected in the supra basal layer indicate an irreversible process during 
carcinogenesis52. 
 
p63 staining characteristics: 
 p63 immunostaining was positive in all the cases of OSCC, leukoplakia, OSF 
and normal oral mucosal samples in the present study. This is in accordance with 
previous reports on p63 expression in OSCC by Choi et al (2002), Bortoluzzi et al 
(2004) and Foschini et al (2004)39,34,6. Positive p63 staining was noted in 100% of 
oral leukoplakia and 100% of OSF samples by Kovesi et al (2006) and Haniffa et al 
(2007) respectively31,30. Bortoluzzi et al (2004), Foschini et al (2004), Chen et al 
(2005) & Haniffa et al (2007) have demonstrated p63 expression in 100% of normal 
oral mucosa samples34,6,,7,30. 
  According to Chen et al (2005), p63 protein is expressed in the basal layers 
of the normal oral mucosa, where it likely serves to maintain the proliferative 
potential of the basal keratinocytes. They authors also stated that upon dysplastic 
change, the dysplastic keratinocytes above the basal layers also shows p63 expression, 
indicating an antidifferentiation effect and proliferative capacity of the dysplastic 
cells7. 
 The mean LI was significantly higher in OSCC (56.8 ± 19.6) and leukoplakia 
(42.3 ± 10.5) when compared to normal mucosa (26.4 ± 9.4) (p=0.00; p=0.00). 
Similar findings have been reported by Foschini et al, who showed that the 
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percentage of positive cells increased from normal to neoplastic mucosa6. In the 
present study, the mean LI was significantly higher in OSCC when compared to oral 
leukoplakia. These findings are in contrast to the studies done by Bortoluzzi et al 
(2004) and Haniffa et al (2007) who did not find significant difference in the 
percentage of p63 positive cells between dysplasia and OSCC34,30.  
 A significantly higher mean LI was noted in OSCC and leukoplakia when 
compared to OSF samples in our study. Studies by Haniffa et al have shown that 
OSF samples showed significantly higher percentage of p63 positive cells than in 
OSCC or leukoplakia30. These authors suggest that the disruption of normal function 
of p53 by mutation may result in compensatory up-regulation of p63. They also state 
that a higher frequency of p53 mutations in OSF might lead to the higher percentage 
of p63 positive cells than that seen in epithelial dysplasia30. 
 In the present study, 90% of leukoplakia, 70% of OSF and 50% of normal 
samples exhibited both basal and supra basal staining. Bortoluzzi et al and Foschini 
et al have demonstrated p63 staining in both basal and supra basal layers of normal 
oral epithelium34,6. Extension of the p63 expression to the superficial layers of the 
normal oral epithelium has been noted in areas of chronic inflammation6. Supra basal 
expression of p63 protein, extending up to the upper spinous layers of the epithelium 
has been reported in oral epithelial dysplasias by Kovesi et al, Haniffa et al and 





Correlation between p53 and p63 staining: 
  We observed a significant positive correlation between the mean LI of p53 
and p63 in OSCC and OSF. Association between p53 and p63 immunoexpression in 
the buccal squamous cell carcinoma was shown by Chen et al38. Another study done 
by Chen et al also showed significant correlation between p53 and p63 expression in 
DMBA-treated hamster buccal pouch carcinomas35.    In our study, correlation was not 
significant in oral leukoplakia and normal mucosa. In leukoplakia, this could be 
probably due to variation in grades of dysplasia seen in our cases. 
 
 To conclude, our study showed that there is increased expression of p53 and 
p63 proteins in OSCC, oral leukoplakia and OSF when compared to normal oral 
mucosa using IHC. These results suggest that alteration of p53 and p63 protein 
expression occur during oral oncogenesis. Further, correlation analysis shows that 
there is a direct correlation between p53 and p63 expression in OSCC and OSF. Thus, 
based on our study findings, we state that both p53 and p63 proteins are increased in 











¾ A total of 70 patients were included in the study, comprising of 20 cases of 
OSCC (group I), 20 cases of leukoplakia (group II), 20 cases of OSF (Group 
III) and 10 patients with normal oral mucosa (group IV), showing mean ages 
of 55.2, 43.6, 36.4 and 29.5 years respectively.  
¾ In group I, 80% were males and 20% were females. In group II, 100% were 
males. 
In group III, 95% were males and 5% were females. In group IV, 40% were 
males and 60% were females. 
¾ The p53 mean LI for group I, II, III and IV were 56.9 ± 21.3, 37.6 ± 12.6, 34.6 
± 8.7 and 15.1 ± 9 respectively; the difference in mean LI among the groups 
was statistically significant (p=0.00). The p63 mean LI for group I, II, III and 
IV were 56.8 ± 19.6, 42.3 ± 10.5, 32.8 ± 12.1 and 26.4 ± 9.4 respectively and 
the difference was statistically significant (p=0.00). 
¾ In group II, p53 staining was seen in the basal layer in 20% and both basal and 
supra basal layers in 80% of the cases. In group III, 40% exhibited basal 
staining, while 60% had both basal and supra basal p53 staining. In group IV, 
20% of the samples had basal p53 staining and 10% had both basal and supra 
basal staining. The tissue localization of p53 staining was significantly 
different among the 3 study groups (p=0.00). 
¾ In group II, 10% of the cases exhibited p63 staining in the basal layer, while 
90% had both basal and supra basal staining. In group III, 30% had basal stain 
and 70% showed basal and supra basal staining. In group IV, basal staining 
was seen in 50% of the samples while both basal and supra basal staining was 
observed in the remaining 50% of the samples. The tissue localization of p63 
staining was not statistically significant among the 3 study groups (p=0.05). 
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¾ p53 and p63 staining showed a significant positive correlation  in group I and 
III (p=0.00; p=0.00). 
 
In conclusion, the results of the current study show that there is 
significantly higher expression of p53 and p63 proteins in OSCC, oral 
leukoplakia and OSF samples when compared to normal oral mucosa. Over-
expression of p63 protein in OSCC, leukoplakia and OSF samples might be 
due to 
• Compensatory up-regulation of p63, resulting from mutation of p53 
gene 
• Transcriptional dysregulation of p63 gene  
However, the 4A4 antibody against p63 protein, which was used in our 
study does not discriminate TA or ∆N type of p63, both of which has opposite 
functions. Further mRNA studies by RT-PCR using isoform-specific primers, 
will ascertain the exact role of p63 in oral carcinogenesis and also its 
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Figure 1: Armamentarium 
 
 










Figure 4: Leukoplakia  Figure 5: Oral submucous fibrosis 
            
 
 
 p53 STAINING IN ORAL SQUAMOUS CELL CARCINOMA 
 
 
     Figure 6: H & E; 10 x    Figure 7: Negative control; 10 x 
                        
                               
 
  
    Figure 8: p53 stain; 10 x                         Figure 9:  p53 stain; 40 x 
                  




 p63 STAINING IN ORAL SQUAMOUS CELL CARCINOMA 
 
 
Figure 10: H & E; 10 x   Figure 11: Negative control; 10 x 
                 
 
 
Figure 12: p63 stain; 10 x                           Figure 13: p63 stain; 40 x                          





 p53 STAINING IN EPITHELIAL DYSPLASIA 
 
 
Figure 14: H & E; 10 x             Figure 15: Negative control; 10 x 




Figure 16: p53 stain; 10 x                         Figure 17: p53 stain; 40 x 






 p63 STAINING IN EPITHELIAL DYSPLASIA 
 
 
Figure 18: H & E; 10 x            Figure 19: Negative control; 10 x 




Figure 20: p63 stain; 10 x    Figure 21: p63 stain; 40 x 





 p53 STAINING IN ORAL SUBMUCOUS FIBROSIS 
 
  
Figure 22: H & E; 10 x                    Figure 23: Negative control; 10 x 




Figure 24: p53 stain; 10 x                                 Figure 25: p53 stain; 40  
                
 
                
 
 
 p63 STAINING IN ORAL SUBMUCOUS FIBROSIS 
 
 
Figure 26: H & E; 10 x     Figure 27: Negative control; 10     





    Figure 28: p63 stain; 10 x                        Figure 29: p63 stain; 40 x                         






p53 STAINING IN NORMAL ORAL MUCOSA 
 
 
Figure 30: H & E; 10                          Figure 31: Negative control; 10 x 




Figure 32: p53 stain; 10 x                           Figure 33: p53 stain; 40 x 






p63 STAINING IN NORMAL ORAL MUCOSA 
 
 
Figure 34: H & E; 10 x   Figure 35: Negative control; 10 x 




    Figure 36: p63 stain; 10 x                    Figure 37: p63 stain; 40 x   
        
Table 1: Mean age distribution among the study groups 
 
Groups Age in years p-value 
Mean SD 




Leukoplakia (Group II) (n=20) 43.6 10.6 
OSF (Groups III) (n=20) 36.4 7.3 
Normal (Group IV) (n=10) 29.5 7.9 























Table 2: Comparison of sex distribution among study groups 
 





Groups Males Females p-value 




OSCC (Group I) (n=20) 16 80 4 20 
Leukoplakia (Group II) 
(n=20) 
20 100 0 0 
OSF (Group III) (n=20) 19 95 1 5 
Normal (Group IV) (n=10) 4 40 6 60 




















Table 3: Comparison of habits among study groups 
 
   Groups 
Habits  
p-value Smoking Chewing** Smoking + 
Chewing 
No habits 











9 45 5 25 6 30 0 0 
OSF (Group 
III) (n=20) 






0 0 0 0 0 10 100 
*p<0.05 is statistically significant at 5% level 


















































Well differentiated 14 70 
Moderately differentiated 4 20 
Poorly differentiated 2 10 











Mild dysplasia 9 45 
Moderate dysplasia 7 35 
Severe dysplasia 4 20 












 Table 6: Comparison of p53 labelling index among study groups 
 
Groups Labelling index P- value 




OSCC(Group I) (n=20) 56.9 21.3 
Leukoplakia (Group II) 
(n=20) 
37.6 12.6 




*p<0.05 is statistically significant at 5% level 
 

















Localization p- value 









4 20 16 80 0 0 
OSF (Group 
III) (n=20) 




2 20 1 10 7 70 





























Table 8: Comparison of p63 labelling index among study groups 
 
Groups Labelling index p- value 
Mean SD  
 
0.00* 
OSCC (Group I) (n=20) 56.8 19.6 
Leukoplakia (Group II) 
(n=20) 
42.3 10.5 
OSF (Group III) (n=20) 32.8 12.1 
Normal (Group IV) (n=10) 26.4 9.4 
*p<0.05 is statistically significant at 5% level 
 















Table 9: Comparison of p63 localization among study groups 
 
 
Groups Localization p- value 
Only Basal Basal + Suprabasal  
 
0.05 
n % n % 
Leukoplakia(GroupII) 2 10 18 90 
OSF(GroupIII) 6 30 14 70 
Normal(GroupIV) 5 50 5 50 
p<0.05 is statistically significant at 5% level 
 
 
      
   
 






















 GRAPH 10: CORRELATION BETWEEN p53 AND p63 IN OSCC 













GRAPH 11: CORRELATION BETWEEN p53 AND p63 IN LEUKOPLAKIA 
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 GRAPH 12: CORRELATION BETWEEN p53 AND p63 IN OSF 











GRAPH 13: CORRELATION BETWEEN p53 AND p63 IN NORMAL 
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